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Great increase in Whole Genome Sequencing (WGS) and
Next Generation Sequencing (here: NGS-CA) approaches
were witnessed in the past few years, since cataloging or
landscaping all possible cancer aberrations appears to be
both scientifically relevant and useful for therapeutic stra-
tegies. This search has been performed through Medline
using NGS with appropriate cancer types/subtypes defini-
tions and paying particular attention to the major over-
views from groups on both sides of the Atlantic (i.e.,
Michael Stratton and Bert Vogelstein: [1] and [2]).
Although the most utilized instruments-technologies so
far are the 454 pyrosequencing apparatuses and the Illu-
mina platform, technology is continuously developing,
such as the Ion-Torrent machines (see below). The scope
here is to overview general pitfalls and perspectives in the
whole area of NGS-CA studies and to suggest probable
trends and prudent recommendations.
Pitfalls
1. Much fewer reports are present today for pediatric
tumors and particularly leukemia/lymphoma in compari-
son to adult cases (ratio 1:10 / 1:20). This is scientifically
counterproductive, as major breakthroughs in our under-
standing of human cancer often originated from pediatric
cancer (also next point). No WGS-NGS studies have
been published so far on neuroblastoma or other pedia-
tric tumors [3].
2. It is apparent that many mutations appeared before
the time of malignant transformation in an age/dependent
fashion. Although the “mutator phenotype” [1][2] is still
discussed, this already suggests that some “drivers” may be
irrelevant for malignancy onset. Further discrepancies
concern the proportion of oncogenes/TSG and the strate-
gies for targeting the relative mutations (today essentially
PKi) [1][2].
3. NGS-CA are biased toward a genetic analysis of
malignancies, defined as CAN-GEN approach [4]. I pre-
viously have [4] and refer here to CAN-EPI for alterations
at the epigenetic level (scarcely studied by NGS-CA), to
CAN-CHROM for aneuploidy/variation in chromosomes
(difficult to study) and to UP-CAN for mechanism(s)
upstream-responsible for cancer-aberration induction
(essentially ignored by NGS-CA studies).
4. Strategies dictated by NGS-CA studies (particularly,
in cases of alterations in EGFR and ALK in lung cancer
and BRAF in melanoma – tested in other tumors) uni-
versally showed that the eventual remissions are brief/
insufficient. Similarly, so called “Lazarus effects” were
described approximately ten years ago and are resur-
rected now for justifying more sequencing expeditions.
Perspectives and Recommendations
1. Further studies should be performed on pediatric can-
cer, where age is clearly less important/determining fac-
tor and where important breakthroughs could be
feasible also in the area of UP-CAN ([4],[5]).
2. Technology should be followed with great attention.
Introduction of the equivalent of the PC for sequencing
– i.e., Ion Torrent - could lead to desperately - needed
new discoveries.
3. Gene-targeting approaches failures, accepted as “fait
accompli”, are rebutted by stating that multiple agents
should be effective. Although big pharma’s do not test
combined agents, this approach should be obviously
encouraged.
4. As per Pitfalls and especially in view of the great het-
erogeneity (intratumoral, intrametastatic, intermetastaticCorrespondence: profrovigatti@gmail.com
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and between patients [1][2]) demonstrated in human can-
cers, additional approaches beside the CAN-GEN and
namely the CAN-EPI, CAN-CHROM and particularly
UP-CAN should be also pursued [4][5] .
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